EBioMedicine (Jan 2024)

Systems biology analysis reveals distinct molecular signatures associated with immune responsiveness to the BNT162b COVID-19 vaccineResearch in context

  • Ivan Odak,
  • Lennart Riemann,
  • Inga Sandrock,
  • Anne Cossmann,
  • Gema Morillas Ramos,
  • Swantje I. Hammerschmidt,
  • Christiane Ritter,
  • Michaela Friedrichsen,
  • Ahmed Hassan,
  • Alexandra Dopfer-Jablonka,
  • Metodi V. Stankov,
  • Leonie M. Weskamm,
  • Marylyn M. Addo,
  • Inga Ravens,
  • Stefanie Willenzon,
  • Anja Schimrock,
  • Jasmin Ristenpart,
  • Anika Janssen,
  • Joana Barros-Martins,
  • Gesine Hansen,
  • Christine Falk,
  • Georg M.N. Behrens,
  • Reinhold Förster

Journal volume & issue
Vol. 99
p. 104947

Abstract

Read online

Summary: Background: Human immune responses to COVID-19 vaccines display a large heterogeneity of induced immunity and the underlying immune mechanisms for this remain largely unknown. Methods: Using a systems biology approach, we longitudinally profiled a unique cohort of female high and low responders to the BNT162b vaccine, who were known from previous COVID-19 vaccinations to develop maximum and minimum immune responses to the vaccine. We utilized high dimensional flow cytometry, bulk and single cell mRNA sequencing and 48-plex serum cytokine analyses. Findings: We revealed early, transient immunological and molecular signatures that distinguished high from low responders and correlated with B and T cell responses measured 14 days later. High responders featured a distinct transcriptional activity of interferon-driven genes and genes connected to enhanced antigen presentation. This was accompanied by a robust cytokine response related to Th1 differentiation. Both transcriptome and serum cytokine signatures were confirmed in two independent confirmatory cohorts. Interpretation: Collectively, our data contribute to a better understanding of the immunogenicity of mRNA-based COVID-19 vaccines, which might lead to the optimization of vaccine designs for individuals with poor vaccine responses. Funding: German Center for Infection Research, German Center for Lung Research, German Research Foundation, Excellence Strategy EXC 2155 “RESIST” and European Regional Development Fund.

Keywords